Abgenix at hold by Jefferies

Abgenix Inc. was maintained at hold by Jefferies & Co., Inc. analyst Adam Walsh. Jefferies expects Amgen's $2.2 billion acquisition offer for Abgenix ($22.50/share) to be consummated shortly after a shareholder vote on March 29. Abgenix reported fourth-quarter 2005 non-GAAP loss per share of $0.48, $0.08 below the analyst's estimate. Shares of the Fremont, Calif., biopharmaceutical company were up 2 cents, or 0.09%, at $22.18 on volume of 3,603,818 shares versus the three-month running average of 3,791,430 shares. (Nasdaq: ABGX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.